Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp after single and multiple dosing

...

Related Keywords

United States ,American ,Curtis Rambaran ,Hansoh Pharma ,Nasdaq ,Journal Of The American Medical Association ,Astrazeneca ,Exchange Commission On ,Silence Therapeutics ,American Medical Association ,Chief Medical Officer ,Securities Litigation Reform Act ,Admission Document ,Annual Report ,Exchange Commission ,Markets ,